Table 4. DHX32 and RGS12 association with clinical response in RA patients according to anti-TNF therapy.
| All anti-TNF | Infliximab | Adalimumab | Etanercept | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SNP (gene) | Minor Allele | Major Allele | MAF | OR(95%CI) | P | OR(95%CI) | P | OR(95%CI) | P | OR(95%CI) | P |
| rs12356233 (DHX32) | G | A | 0.39 | 1.01(0.71–1.43) | 0.96 | 0.65(0.37–1.15) | 0.14 | 2.7(1.3–5.61) | 0.0064* | 0.85(0.47–1.56) | 0.61 |
| rs2857859 (RGS12) | T | C | 0.3 | 0.87(0.59–1.28) | 0.48 | 0.8(0.43–1.48) | 0.48 | 0.98(0.45–2.15) | 0.96 | 0.89(0.47–1.71) | 0.73 |
| rs4690093 (RGS12) | G | A | 0.29 | 0.75(0.51–1.12) | 0.16 | 0.95(0.52–1.71) | 0.85 | 0.4(0.17–0.98) | 0.04 | 0.88(0.44–1.76) | 0.71 |
MAF: minor allele frequency in all RA patients; OR: odds ratio; CI: odds ratio confidence interval; P: nominal significance in association test with clinical response at week 12.
*significant (P<0.05) after multiple test correction.